Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
D. Western Therapeutics Institute Inc
Deli Therapeutics Inc
E-scape Bio Inc
Guangzhou DM Intelligence Ltd
H. Lundbeck AS
ICB Intertiol Inc
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
Neuron23 Inc
Oncodesign SA
Shape Therapeutics Inc
Voronoi Group
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antibody 1 to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-975 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESB-5070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-7915 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-1337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ION-859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ODS-2005294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06447475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LRRK-2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK-2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
May 01, 2021: Phase 1b studies of its LRRK2 inhibitor, BIIB122/DNL151, supporting late-stage development plans in Parkinson’s Disease
Aug 06, 2020: Biogen and Deli to collaborate on LRRK2 program for Parkinson’s Disease and certain tv platform-ebled programs for neurodegenerative diseases
Aug 06, 2020: Deli Therapeutics announces decision to advance DNL151 into late stage clinical studies in Parkinson’s Patients
Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
Sep 05, 2019: Deli begins dosing Parkinson’s patients in Phase Ib trial
Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Desigtion for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
Dec 10, 2018: Deli Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson’s disease
Aug 01, 2018: Deli Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
Dec 20, 2017: Deli Therapeutics Provides Update on DNL151
Dec 20, 2017: Deli Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its nocyclix technology platform for next generation kise inhibitors
Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Arrien Pharmaceuticals LLC, 2021
Pipeline by D. Western Therapeutics Institute Inc, 2021
Pipeline by Denali Therapeutics Inc, 2021
Pipeline by E-scape Bio Inc, 2021
Pipeline by Guangzhou DM Intelligence Ltd, 2021
Pipeline by H. Lundbeck AS, 2021
Pipeline by ICB International Inc, 2021
Pipeline by Imago Pharmaceuticals Inc, 2021
Pipeline by Ionis Pharmaceuticals Inc, 2021
Pipeline by Lead Discovery Center GmbH, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neuron23 Inc, 2021
Pipeline by Oncodesign SA, 2021
Pipeline by Shape Therapeutics Inc, 2021
Pipeline by Voronoi Group, 2021
Dormant Projects, 2021